St. John's Wort Versus Placebo in Social Phobia

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the effectiveness of St. John’s Wort as compared to placebo (an inactive substance) in the treatment of outpatients with social phobia.

Clinical Trial Description

Social Phobia is a prevalent and debilitating condition, with a lifetime prevalence rate to be 13.3 percent. Socially phobic patients have been found to be functionally impaired in the areas of education, employment and social relationships, to have poorer quality of life, and increased suicidal ideation and psychiatric comorbidity. Double-blind studies have found benzodiazepines, selective and non-selective MAOI inhibitors, several SSRIs, and the anticonvulsants pregabalin and gabapentin to be effective. However, side effects with these compounds suggests the need for better tolerated compounds, e.g., in the paroxetine multi-center trial (the only drug with an FDA approved indication), 27 percent reported somnolence, 26 percent nausea, and 37 percent of males reported delayed ejaculation; 34 percent of patients discontinued the trial early. There has been considerable worldwide interest in St. John's Wort (SJW) (Hypericum perforatum) as a treatment of mild to moderate depression. There have been 23 randomized trials suggesting SJW is more effective than placebo for the treatment of outpatients with mild to moderate depression. SJW is very well tolerated with mild side effects observed in only 2.5 percent of cases in a large (3250 patients) drug monitoring study. Pharmacokinetic studies have found Hypericum to have affinity for serotonin, dopamine and GABA alpha and GABA beta receptors, each of which have been implicated in social phobia, thus there is a suggestion that SJW may be effective for this disorder.

This will be a 12-week, double blind, placebo-controlled trial, designed to generate effect size data that will be used to determine sample size needed to power a definitive study. Forty patients will be randomized to either SJW (LI 160) or matching placebo. This will be a flexible-dose design, starting at 300 mg tid to a maximum of 1800 mg total per day. An intent-to-treat analysis will be employed. Subjects will be evaluated weekly for two weeks, then bi-weekly thereafter. The primary outcome measure will be the change from baseline to endpoint on the Liebowitz Social Anxiety Scale. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Phobic Disorders

Clinical Trial Details

NCT number	NCT00035412
Study type	Interventional
Source	National Center for Complementary and Integrative Health (NCCIH)
Contact
Status	Completed
Phase	Phase 2
Start date	December 2001
Completion date	August 2004

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01963806` - ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder	N/A
Completed	`NCT00121069` - Study of Escitalopram in the Treatment of Specific Phobia	Phase 2/Phase 3
Recruiting	`NCT03653923` - Neurophysiological Correlates of Exposition Therapy in Spider Phobia	N/A
Completed	`NCT00184106` - RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo	Phase 4
Completed	`NCT00051220` - Treatment for Specific Phobias in Children	Phase 1/Phase 2
Completed	`NCT02310152` - Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE)	N/A
Completed	`NCT02387047` - Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly	N/A
Completed	`NCT00000370` - Treatment of Social Phobia	N/A
Completed	`NCT03012035` - The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants	N/A
Completed	`NCT02007694` - Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants	Phase 2/Phase 3
Active, not recruiting	`NCT03188575` - Effectiveness & Cost-effectiveness of Internet-delivered Interventions for Depression and Anxiety Disorders in IAPT	N/A
Completed	`NCT02432703` - A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder	Phase 2
Terminated	`NCT01574014` - Glucocorticoid Treatment for Social Phobia	Phase 2
Completed	`NCT00734422` - Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants	Phase 2/Phase 3
Not yet recruiting	`NCT02336802` - Threat-Avoidance Learning in Anxiety Patients	N/A
Completed	`NCT01361074` - In Vivo Versus Augmented Reality Exposure for Small Animal Phobia	N/A
Completed	`NCT00104195` - A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions	Phase 1
Completed	`NCT00128401` - Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia	Phase 2
Recruiting	`NCT02020824` - Virtual Reality and Concept of Control in the Treatment of Acrophobia	N/A
Terminated	`NCT01623583` - Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.